



Medicine and Health Sciences
Geneeskunde en Gesondheidswetenskappe
EzoNyango nezeeNzululwazi kwezeMpilo

Transplantation in the HIV Era: ***Should HIV positive donor organs be transplanted in HIV negative recipients?***

No conflict to declare

- This presentation reflects my personal view and should not be construed to represent any third party's view or policy.

Introduction

- High success rate of solid organ transplantation – even for HIV patients
 - Improved modern immunosuppression
- Primary limitation is available donor organs
 - +/- 500 donors for > 100 000 on waiting lists in the USA
- Need to increase the donor pool
- Organs rejected due to safety
- Disease free organs not guaranteed
 - CMV
 - Hep C
 - HIV: reported cases in the literature

Introduction

- Using HIV-infected donors is beneficial for HIV-infected recipients
 - However, potential increased risk of infections in recipients
 - So far good 5 year survival*
 - Caution: limited data yet available
- HIV Organ Policy Equity (HOPE) Act of the USA legalizes HIV-infected organ donation transplantation research#

*Muller et al. NEJM 2010, #Malani P. JAMA 2016



Concerns regarding the HIV+ donor

- HIV superinfection
- Protease inhibitor use
- Latent opportunistic infection
- Acute rejection

Richterman A & Blumberg E. Curr Inf Dis Rep 2015



Concerns regarding the HIV+ donor

- HIV superinfection
 - Important if HIV infections are heterogenous (different clades etc)
 - No detectable viral load as requirement
 - Sirolimus act as a reservoir modifying agent in HIV
 - Measure HIV DNA and RNA in donor's urine to determine viral load and predict risk of superinfection*
- Protease inhibitor use
- Latent opportunistic infection
- Acute rejection

Richterman A & Blumberg E. Curr Inf Dis Rep 2015

*Canaud G et al. J Am Soc Nephrol 2014



Concerns regarding the HIV+ donor

- HIV superinfection
- Protease inhibitor use
 - Potential significant medicine interactions with anti-rejection medicines
 - Donor controlled viral load – lead to need for protease inhibitor containing regimen in recipient
- Latent opportunistic infection
- Acute rejection

Richterman A & Blumberg E. Curr Inf Dis Rep 2015



Concerns regarding the HIV+ donor

- HIV superinfection
- Protease inhibitor use
- Latent opportunistic infection
 - History of opportunistic infections in donor may necessitate prophylaxis in recipient
- Acute rejection

Richterman A & Blumberg E. Curr Inf Dis Rep 2015



Concerns regarding the HIV+ donor

- HIV superinfection
- Protease inhibitor use
- Latent opportunistic infection
- Acute rejection in HIV-infected recipients
 - Immune dysregulation
 - Suboptimal dosing of antirejection medicines
 - Reinfection of organ (example kidney)

Richterman A & Blumberg E. Curr Inf Dis Rep 2015



Organ allocation

- Scarce resources
- Need a fair system of distribution
- Different resource allocation systems – each with disadvantages as well



United Network for Organ Sharing

- Organ allocation – 3 principles
 - sickest-first (current medical condition)
 - first-come, first-served (waiting time)
 - prognosis (antigen, antibody, and blood type matching between recipient and donor)
- Advantage – Flexibility
- Disadvantage – prognosis often less important

Persad G et al. Lancet 2009



Ethical arguments

- No for HIV+ to donate to HIV- patients
- Yes for HIV+ to donate to HIV- patients



No for HIV+ to donate to HIV- patients

- Dealing with a particular vulnerable group of patients
- Create an additional burden of disease
- Unknown what other complications may occur
- May need life long HAART
- May have additional organ damage due to HIV infection
eg end stage renal disease due to HIV
- Need for more data regarding HIV+ recipients' long term survival after transplant
 - Quality adjusted life years (QALY)
 - Disability adjusted life years (DALY)



Yes for HIV+ to donate to HIV- patients

- Autonomy
- Beneficence/Non-maleficence
- Justice

Richterman A & Blumberg E. Curr Inf Dis Rep 2015

Wispelwey BP et al. J Med Ethics 2015



Yes for HIV+ to donate to HIV- patients

- Autonomy
 - Informed patient decision-making: process intensive
 - Not much different from the CMV risk for recipients of CMV+ donors
- Beneficence/non-maleficence
- Justice



Yes for HIV+ to donate to HIV- patients

- Autonomy
 - Informed patient decision-making: process intensive
 - Not much different from the CMV risk for recipients of CMV+ donors
- Beneficence/non-maleficence
 - Must assist in allowing more potential recipients access to organs
 - Improved quality of life
 - Anyway receiving immunosuppression, added ART may not be that problematic
- Justice



Yes for HIV+ to donate to HIV- patients

- Autonomy
 - Informed patient decision-making: process intensive
 - Not much different from the CMV risk for recipients of CMV+ donors
- Beneficence/non-maleficence
 - Improved quality of life
 - Anyway receiving immunosuppression, added ART may not be that problematic
- Justice
 - Improved chance of transplantation



Need research: HIV+ donor to HIV- recipient

- Must determine the risk-benefit ratio
- Two approaches to apply to risk-benefit assessment
 - Component analysis
 - Net risks test

Risk-Benefit Assessment: Component Analysis



- Requires state of clinical equipoise
 - Genuine uncertainty
- Posed risks acceptable in the context of the expected benefits
- Applied to this scenario
 - Risks of HIV infection versus life saving transplantation
 - Normal life expectancy on HAART for HIV-infected patients
 - Strict guidelines to be developed – similar to HOPE guidelines

Risk-Benefit Assessment: Net Risks Test



| Intervention | Risk/Burden-Benefit Assessment |
|----------------------------|---|
| Organ transplantation | Known risks |
| HIV-infected donor's organ | Burden: Potential HIV-recipient infection |
| Net overall risk/burden | *Moderate to severe |

*Must minimize risk/burden – again need strict guidelines



Proposed guidelines for HIV+donor to HIV-recipient

- Standardised screening for HIV in solid tumour organ donors – Both HIV-Abs & Nucleic acid amplification testing (NAT)
- Risk of HIV infection in donated organ unknown – Donor should be on HAART with no detectable viral load
 - Need research into latent infection in organs to be transplanted eg kidneys, liver
- Donor should be on first line HAART with not potential for HIV resistance
- Donor should not have any opportunistic infections (need to investigate cause of death carefully)
- Informed consent – lengthy process
 - Vulnerable population
 - Potential need for lifelong HAART
 - Precedent all ready exists with regards to potential fatal CMV infection in organ transplantation



Propose HOPE Criteria: National Institute of Allergy and Infectious Diseases (NIAID) (HIV+ recipients)

| | New HIV infection diagnosis | History of HIV infection | Living donor |
|------------------------------------|-----------------------------|--------------------------|--|
| CD4 count (cells/mm ³) | ≥200 | ≥200 | ≥500 for 6 months prior to organ procurement |
| HIV VL (copies/mL) | No requirement | ≤50 | ≤50 |
| Antiretroviral resistance | ≤1 antiretroviral class | ≤1 antiretroviral class | ≤1 antiretroviral class |
| Opportunistic infection | None active | None active | None active No history of: Chronic cryptosporidiosis CNS lymphoma Progressive multifocal leukoencephalopathy |

Adapted: Odim J. ICAAC 2014, Washington

Conclusion

- Based on respect for autonomy and from a beneficence/non-maleficence perspective
 - Allow HIV+ organ donation to HIV- recipient subject to
 - Need more research regarding outcome of HIV+ recipients
 - Need intensive standardized screening of organs for HIV infection
 - Strict criteria as mentioned namely donor on HAART with no detectable viral load and complicated opportunistic infections

Thank you for the invitation

